Article
Biochemistry & Molecular Biology
Benjamin G. G. Bitler, Courtney A. A. Bailey, Tomomi M. M. Yamamoto, Alexandra McMellen, Hyunmin Kim, Zachary L. L. Watson
Summary: PARP inhibitors kill cancer cells by stalling DNA replication and preventing DNA repair. Resistance to PARP inhibitors is becoming a clinical problem in the treatment of high grade serous ovarian carcinoma (HGSOC). This study investigates the expression and activities of histone acetyltransferases (HATs) and epigenetic readers in PARP inhibitor-resistant HGSOC, and assesses the therapeutic potential of targeting H3K14ac or associated proteins.
MOLECULAR CARCINOGENESIS
(2023)
Article
Biochemistry & Molecular Biology
Junping Pan, Xiaochuan Chen, Lin Yang, Yanwen Song, Jing Liu, Li Li, Yibin Lin, Lina Tang, Sufang Qiu, Qin Xu
Summary: This study identified and validated a prognostic gene signature associated with the tumor immune microenvironment in HGSOC. The signature was correlated with immunological characteristics, mutational profiles, and the efficacy of platinum-based chemotherapy and immunotherapy. CD2 was identified as a potential biomarker for predicting immune efficacy.
FRONTIERS IN BIOSCIENCE-LANDMARK
(2023)
Article
Oncology
Chao Meng, Yue Sun, Guoyan Liu
Summary: Mitochondrial metabolism-related genes (MMRGs) were found to be associated with the prognosis of high-grade serous ovarian cancer (HGSOC) patients. A prognostic model based on IDO1, TNFAIP8L3, GPAT4, SLC27A1, ACSM3, ECI2, PPT2, and PMVK was established, and drugs associated with these genes were identified. The study also revealed the relationship between MMRGs and the tumor immune microenvironment.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Natalia Izycka, Mikolaj Piotr Zaborowski, Lukasz Ciecierski, Kamila Jaz, Sebastian Szubert, Cezary Miedziarek, Marta Rezler, Kinga Piatek-Bajan, Aneta Synakiewicz, Anna Jankowska, Marek Figlerowicz, Karolina Sterzynska, Ewa Nowak-Markwitz
Summary: This study aimed to identify cancer stem cell markers and their association with clinical outcomes in High-Grade Serous Ovarian Cancer. The results showed that ALDH1A1, CD44, EPCAM, LGR5, POU5F1, and THY1 levels may serve as prognostic factors and help predict treatment response in ovarian cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Shuna Liu, Ming Wu, Fang Wang
Summary: Ovarian cancer presents a serious threat to women's health due to its low early diagnosis rate and tendency for metastasis and recurrence. Conventional treatment involving platinum and paclitaxel chemotherapy based on surgery may not effectively address the recurrence and progression of the disease. By understanding the molecular pathways involved in ovarian cancer recurrence and progression, biomarker-guided treatment options have the potential to significantly improve patient prognosis and lead to personalized treatment strategies.
Article
Oncology
Nan Zhang, Zhiyou Yang, Yue Jin, Shanshan Cheng, Jiani Yang, Yu Wang
Summary: The low expression of circ_0078607 in high-grade serous ovarian cancer (HGSOC) is associated with poor clinical outcomes, making it a potential predictor for unfavorable progression-free survival (PFS) and overall survival (OS) in patients.
CANCER MANAGEMENT AND RESEARCH
(2021)
Review
Biochemistry & Molecular Biology
Bryce Wallis, Katherine Redd Bowman, Phong Lu, Carol S. Lim
Summary: It is well known that p53 mutations are common in cancer tumors, including ovarian cancer. Ovarian cancer is often diagnosed at later stages and has a low survival rate, especially for high-grade serous ovarian carcinoma (HGSOC) which has a high prevalence of p53 mutations. Previous p53-based therapies for ovarian cancer have faced challenges and limited success. This review discusses the failures of historical p53-targeted therapeutics and the potential for new generation therapies.
Review
Pharmacology & Pharmacy
Chuanlin Wang, Pengning Gao, Jiali Xu, Shanling Liu, Wenda Tian, Jiayu Liu, Lan Zhou
Summary: This article reviews the role of natural phytochemicals in alleviating the side effects of BRCA mutant ovarian cancer cells and PARP inhibitors, and finds that these substances have significant alleviating effects on atherosclerosis, nausea, and vomiting.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Emanuele Perrone, Riccardo Tudisco, Pia Clara Pafundi, Davide Guido, Alessandra Ciucci, Enrica Martinelli, Gian Franco Zannoni, Alessia Piermattei, Saveria Spadola, Giulia Ferrante, Claudia Marchetti, Giovanni Scambia, Anna Fagotti, Daniela Gallo
Summary: This study explored the relationship between hormone receptor status and BRCA1/2 mutation in high-grade serous ovarian carcinoma (HGSOC) patients. The results showed interesting differences in receptor expression patterns and their association with outcomes between BRCA-mutated and BRCA wild-type women. The findings suggest a potential role of estrogen-mediated pathways in BRCA1/2-associated HGSOC tumorigenesis, revealing a possible therapeutic potential for targeting this interaction.
Article
Oncology
Daniel Martin Klotz, Theresa Link, Pauline Wimberger, Jan Dominik Kuhlmann
Summary: The study investigated the clinical relevance of circulating HGF in serum of ovarian cancer patients. Elevated levels of sHGF were found to be an independent predictor for shorter overall survival, proposing sHGF as an independent prognostic biomarker for ovarian cancer. Furthermore, sHGF could be implemented into clinical diagnostics as a CA125 auxiliary tumor marker for individualized prognosis stratification and therapy monitoring.
MOLECULAR ONCOLOGY
(2021)
Article
Medicine, General & Internal
Rachel Kerslake, Suzana Panfilov, Nashrah Mustafa, Marcia Hall, Ioannis Kyrou, Harpal S. Randeva, Emmanouil Karteris, Richard Godfrey
Summary: This study investigates the circulating lactate levels and the expression of lactate receptor HCAR1 in patients with high-grade serous ovarian cancer (HGSOC). The results show significantly elevated lactate levels in OvCa patients and overexpression of the HCAR1 gene in OvCa. The findings suggest that circulating lactate may serve as a potential screening biomarker for ovarian cancer.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Samantha Batman, Koji Matsuo, Paulette Mhawech-Fauceglia, Elizabeth Munro, Mercedes Weisenberger, Allison Allen, Sonali Joshi, Hiroko Machida, Shinya Matsuzaki, Tatjana Bozanovic, Tanja Pejovic
Summary: Increased expression of PD-L2 is associated with decreased survival in epithelial ovarian carcinoma, and is correlated with other immune biomarkers, suggesting potential for PD-L2-based immunotherapy in treating ovarian cancer. Interactions between tumor DNA repair proteins and the immune microenvironment play a crucial role in determining tumor progression and survival.
Article
Oncology
Tong Shu, Zhipeng Zhou, Jing Bai, Xiao Xiao, Min Gao, Nan Zhang, Hongguo Wang, Xuefeng Xia, Yunong Gao, Hong Zheng
Summary: This study investigated the predictive significance of T-cell receptor (TCR) repertoire diversity in high grade serous ovarian cancer (HGSOC) patients receiving poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy. The results showed that patients receiving PARPi had more stable TCR repertoires, and an increase in TCR diversity after three months of PARPi treatment was associated with longer progression-free survival and better response to PARPi.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Marko Hojnik, Natasa Kenda Suster, Spela Smrkolj, Damjan Sisinger, Snjezana Frkovic Grazio, Ivan Verdenik, Tea Lanisnik Rizner
Summary: This study evaluated the levels of AKR1B1 and AKR1B10 in patients with high-grade serous ovarian cancer and their association with clinicopathological characteristics, survival, and response to chemotherapy. The results showed that higher AKR1B1 levels were associated with better disease-free survival, making it a potential prognostic biomarker for this cancer. However, AKR1B1 and AKR1B10 were not associated with different responses to chemotherapy.
Article
Pathology
Svenja Kolb, Inga Hoffmann, Nanna Monje, Mihnea P. Dragomir, Paul Jank, Philip Bischoff, Carlotta Keunecke, Jonathan Pohl, Catarina Alisa Kunze, Sofya Marchenko, Wolfgang D. Schmitt, Hagen Kulbe, Christine Sers, Jalid Sehouli, Elena Ioana Braicu, Carsten Denkert, Silvia Darb-Esfahani, David Horst, Bruno V. Sinn, Eliane T. Taube
Summary: This study highlights the significant prognostic role of the LRP1B protein in tubo-ovarian high-grade serous carcinoma, showing that its high expression is associated with prolonged overall survival and progression-free survival in patients.
Article
Oncology
Marta Grzeski, Eliane T. Taube, Elena Braicu, Jalid Sehouli, Veronique Blanchard, Oliver Klein
Summary: In this proof-of-concept study, MALDI mass spectrometry imaging (MALDI-MSI) combined with sialic acid derivatization was used to investigate the distribution of neutral and sialylated N-glycans in epithelial ovarian cancer (EOC) and borderline ovarian tumor (BOT) tissues. The study found that ff2,6- and ff2,3-sialylated N-glycans were enriched in tumor and adjacent tumor-stroma regions in EOC tissue. Similar N-glycosylation patterns were also observed in BOT tissue, suggesting that regio-specific N-glycan distribution may already occur in non-malignant ovarian pathologies.
Article
Oncology
Salem Abobaker, Hagen Kulbe, Eliane T. Taube, Silvia Darb-Esfahani, Rolf Richter, Carsten Denkert, Paul Jank, Jalid Sehouli, Elena Ioana Braicu
Summary: This study investigated the correlation of BMI-1 expression in mOC patients and found no significant association with patient age, stage, lymph node status, and family history. Additionally, BMI-1 expression was not associated with progression-free survival.
ANTICANCER RESEARCH
(2022)
Article
Oncology
Philip Bischoff, Alexandra Trinks, Jennifer Wiederspahn, Benedikt Obermayer, Jan Patrick Pett, Philipp Jurmeister, Aron Elsner, Tomasz Dziodzio, Jens-Carsten Rueckert, Jens Neudecker, Christine Falk, Dieter Beule, Christine Sers, Markus Morkel, David Horst, Frederick Klauschen, Nils Bluethgen
Summary: This study used single-cell RNA sequencing to analyze lung carcinoid tumors and normal lung tissue, revealing cellular heterogeneity in the tumor cells. Noninflammatory myeloid cells were enriched in the immune microenvironment, while tumor-associated endothelial cells had distinct gene expression profiles. Additionally, the study found that single-cell gene signatures of pericytes and myofibroblasts had prognostic value.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Carlotta Keunecke, Hagen Kulbe, Felix Dreher, Eliane T. Taube, Radoslav Chekerov, David Horst, Michael Hummel, Thomas Kessler, Klaus Pietzner, Wanja Kassuhn, Florian Heitz, Mustafa Z. Muallem, Susan M. Lang, Ignace Vergote, Oliver Dorigo, Hedwig Lammert, Andreas du Bois, Tim Angelotti, Christina Fotopoulou, Jalid Sehouli, Elena I. Braicu
Summary: This study aimed to discover and validate a predictive panel for surgical outcome of residual tumor mass after first-line debulking surgery. The Nanostring method and immunohistochemistry testing were used to validate a set of predictive genes and predict the presence of miliary carcinomatosis patterns. The results showed that tissue-based biomarkers cannot reliably predict post-operative residual tumor.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Sofya Marchenko, Iris Piwonski, Inga Hoffmann, Bruno Valentin Sinn, Catarina Alisa Kunze, Nanna Monje, Jonathan Pohl, Hagen Kulbe, Wolfgang Daniel Schmitt, Sylvia Darb-Esfahani, Elena Ioana Braicu, Ann-Christin von Bruenneck, Jalid Sehouli, Carsten Denkert, David Horst, Korinna Joehrens, Eliane Tabea Taube
Summary: The study found that higher proportions of regulatory T cells (Tregs) and lower ratios of T helper 17 cells (Th17 cells) were associated with better overall survival in high-grade serous tubo-ovarian carcinoma. This research is important for understanding the impact of the tumor microenvironment on tumor development.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Immunology
Julian Pohl, Philip Bischoff, Robert Oellinger, Wenzel Schoening, Georg Lurje, Johann Pratschke, David Horst, Frank Tacke, Alexander Wree
Summary: Metamizole, a commonly prescribed analgetic drug, can cause liver injury. Although there are only a few reported cases of metamizole-associated liver injury, it can lead to acute liver failure requiring liver transplantation. A recent study from Germany reported a larger cohort of metamizole-related liver injury cases, drawing wider attention to this issue. In our study, we report two cases of acute liver failure requiring emergency liver transplantation due to the use of metamizole as a pain medication. Pathology assessment confirmed the diagnosis of metamizole-associated liver injury. This rare but potentially overlooked adverse drug effect should be considered as a differential diagnosis in cases of cryptogenic liver failure.
TRANSPLANTATION PROCEEDINGS
(2022)
Article
Oncology
Jacek Glajzer, Dan Cacsire Castillo-Tong, Rolf Richter, Ignace Vergote, Hagen Kulbe, Adriaan Vanderstichele, Ilary Ruscito, Fabian Trillsch, Alexander Mustea, Caroline Kreuzinger, Charlie Gourley, Hani Gabra, Eliane T. Taube, Oliver Dorigo, David Horst, Carlotta Keunecke, Joanna Baum, Timothy Angelotti, Jalid Sehouli, Elena Ioana Braicu
Summary: This study evaluates the impact of BRCA gene status on tumor dissemination, surgical outcome, and survival in ovarian cancer patients. BRCA mutation was associated with younger age, more extensive tumor involvement, higher debulking rates, and prolonged overall survival. The study suggests considering BRCA mutation status in patient selection for cytoreductive surgery.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Jana Ihlow, Nanna Monje, Inga Hoffmann, Philip Bischoff, Bruno Valentin Sinn, Wolfgang Daniel Schmitt, Catarina Alisa Kunze, Sylvia Darb-Esfahani, Hagen Kulbe, Elena Ioana Braicu, Jalid Sehouli, Carsten Denkert, David Horst, Eliane Tabea Taube
Summary: Recent advances in molecular medicine have highlighted the potential therapeutic targets of G-protein coupled receptors (GPCRs) in ovarian cancer, particularly the regulator of G protein signaling 2 (RGS2). This study retrospectively analyzed the expression and prognostic value of RGS2 in high-grade serous ovarian cancer (HGSOC). The results showed that low protein expression of RGS2 was associated with inferior overall survival and progression-free survival. Further exploration is needed to understand the functional role of RGS2 in HGSOC and its implications for new drug discovery.
Editorial Material
Oncology
Jacek Glajzer, Dan Cacsire Castillo-Tong, Rolf Richter, Ignace Vergote, Hagen Kulbe, Adriaan Vanderstichele, Ilary Ruscito, Fabian Trillsch, Alexander Mustea, Caroline Kreuzinger, Charlie Gourley, Hani Gabra, Eliane T. Taube, Oliver Dorigo, David Horst, Carlotta Keunecke, Joanna Baum, Timothy Angelotti, Jalid Sehouli, Elena Ioana Braicu
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Philipp Keyl, Philip Bischoff, Gabriel Dernbach, Michael Bockmayr, Rebecca Fritz, David Horst, Nils Bluethgen, Gregoire Montavon, Klaus-Robert Mueller, Frederick Klauschen
Summary: The molecular heterogeneity of cancer cells contributes to the often partial response to targeted therapies and relapse of disease due to the escape of resistant cell populations. Single-cell sequencing has limitations in understanding this heterogeneity, and scGeneRAI is an explainable deep learning approach that can infer gene regulatory networks from single-cell RNA sequencing data to provide functional insights. Our method reveals characteristic network patterns for tumor cells and normal epithelial cells and allows the reconstruction of networks at the level of single cells, which helps characterize the heterogeneity of gene regulation within and across tumors.
NUCLEIC ACIDS RESEARCH
(2023)
Article
Pathology
Svenja Kolb, Inga Hoffmann, Nanna Monje, Mihnea P. Dragomir, Paul Jank, Philip Bischoff, Carlotta Keunecke, Jonathan Pohl, Catarina Alisa Kunze, Sofya Marchenko, Wolfgang D. Schmitt, Hagen Kulbe, Christine Sers, Jalid Sehouli, Elena Ioana Braicu, Carsten Denkert, Silvia Darb-Esfahani, David Horst, Bruno V. Sinn, Eliane T. Taube
Summary: This study highlights the significant prognostic role of the LRP1B protein in tubo-ovarian high-grade serous carcinoma, showing that its high expression is associated with prolonged overall survival and progression-free survival in patients.
Article
Oncology
Inga Hoffmann, Mihnea P. Dragomir, Nanna Monje, Carlotta Keunecke, Catarina Alisa Kunze, Simon Schallenberg, Sofya Marchenko, Wolfgang D. Schmitt, Hagen Kulbe, Jalid Sehouli, Ioana Elena Braicu, Paul Jank, Carsten Denkert, Silvia Darb-Esfahani, David Horst, Bruno V. Sinn, Christine Sers, Philip Bischoff, Eliane T. Taube
Summary: This study reveals that IDO1 expression is associated with prognostic outcomes in high-grade serous ovarian cancer (HGSOC). High IDO1 expression is linked to improved survival and reduced recurrence, as well as increased tumor-infiltrating lymphocytes.
Article
Pharmacology & Pharmacy
Ayk Waldow, Laura-Sophie Beier, Janine Arndt, Simon Schallenberg, Claudia Vollbrecht, Philip Bischoff, Marti Farrera-Sal, Florian N. Loch, Christian Bojarski, Michael Schumann, Lars Winkler, Carsten Kamphues, Lukas Ehlen, Joerg Piontek
Summary: Claudins regulate paracellular permeability, contribute to epithelial polarization and are dysregulated during inflammation and carcinogenesis. Variants of the claudin-binding domain of Clostridium perfringens enterotoxin (cCPE) are highly sensitive protein ligands for generic detection of a broad spectrum of claudins. This study used cCPE fusion proteins to specifically and efficiently detect claudin expression, localization and tight junction dysregulation in various models of gastrointestinal epithelia.
